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OROTIC ACIDURIA 
 
By Aliah Fonteh 
 
CASE REPORT I1 
 
Overview 
 
Uridine monophosphate synthase (UMPS) is a bifunctional enzyme with the catalytic 
sites for orotate phosphoribosyl pyrophosphate transferase (OPRT) and orotidine monophosphate 
decarboxylase (OMPDC). The conversion of orotic acid to uridine-5’PO4 is catalyzed by UMPS. 
Orotic aciduria can occur whether one or both of these enzymes are impaired. In 1968 when this 
case was presented, only three previous patients homozygous for a defect in the enzymes OPRT 
and OMPDC had been reported. A pedigree analysis was utilized to focus on the genotype of 
family members four generations before the patient. The pedigree revealed family members 
heterozygous for hereditary orotic aciduria type I. The pattern of inheritance for hereditary orotic 
aciduria type I is autosomal recessive. The enzyme activity for the patient’s father, siblings, and 
niece revealed “borderline” enzyme activity.  
 
History, Initial Symptoms, and Laboratory Examination 
 
On April 1, 1965, a 6 lb. 7 ¾ oz. female patient was born to normal 21-year old parents. 
Abnormalities in patient hemoglobin leading to anemia were first evidenced after two months of 
life. Administration of 30 milligrams (mg) of iron and 50 mg of Vitamin C daily did not improve 
the patient’s anemic conditions. After hospital admission to North Carolina Baptist Hospital in 
Winston-Salem, NC, the six-month old patient was found to have pallor and bilateral strabismus. 
Laboratory analysis, bone marrow analysis, and a peripheral blood smear revealed erythrocyte 
dysfunction. Erythroid hyperplasia was also discovered after the bone marrow analysis. The 
peripheral blood smear revealed anisocytosis, poikilocytosis, hypersegmentation of granulocytes, 
and mild hypochromia. The initial treatment plan was intramuscular administration of 15 mg and 
7.5 mg of folic acid for five days each, respectively. Oral administration of folic acid for two 
weeks, then 30 microgram (μg) rotations of Vitamin B12 every other day were administered. 
Vitamin B12 supplementation was repeated three times.  
 
Diagnostics 
 
Diagnostic exams included erythrocyte enzyme assays and urinary screening tests. The 
patient’s OMPDC and OPRT activity was 0.02 and 0.96, respectively. Control values for 
OMPDC activity were 0.79 and 1.9, while control values for OPRT were 5.4, 4.1, and 3.6. The 
measure of the conversion of orotic acid to uridine-5’PO4 was also studied. Measurement of 
these values was 0.02 compared to control values of 0.83, 1.5, and 2.4. Overall, the patient’s 
enzyme activity for both OMPDC and OPRT was very low compared to controls.  
 
Symptoms 
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The patient’s main symptoms included megaloblastic anemia, orotic aciduria and orotic 
acid crystallization, growth delays, and developmental delays. Early patient symptoms required 
an erythrocyte transfusion twice, and by early 1966, the patient was first observed to have orotic 
acid crystalluria. The crystalluria became observable following dehydration and gastroenteritis.  
Orotic acid excretion for the patient was 3.89 gm per gram of creatinine, compared to other cases 
which may have up to 1,000 times the orotic acid excretion quantity compared to normal adults. 
The patient was experiencing growth and length delay because the patient’s weight and length 
were in the 10th and 50th percentiles, respectively. 
 
Management and Results of Treatment 
 
At eleven months, the administration of 1.5 gm/day of oral uridine began. Reticulocyte 
development spiked within two days, hemoglobin concentration rose from 7.8 gm/100 mL at the 
first hospital admission to 12.3 gm/100 mL on the fifth day of therapy, and the leukocyte count 
increased to a range of 3900 to 12000 per m3 during therapy.  Bone marrow analysis after two 
months did not reveal any abnormalities. In addition, the child’s development was evident due to 
increased activity and appetite. Compared to the weight and height percentiles at six months, by 
eighteen months the patient was in the 50th and 90th percentiles, respectively. Mental delays 
were not present when the patient was assessed at age 2.5.  
The daily dosage of 1.5 gm was significant for the reduction in orotic acid output, and 
this measure helped to reduce the risk of urinary tract obstruction due to the crystallized orotic 
acid. Oral uridine is responsible for reticulocyte development and correction of megaloblastic 
changes of the bone marrow. Upon recognition that Vitamin B12 and iron were not correcting 
the anemia, the administration of oral uridine may have occurred early enough to prevent further 
damage such as mental retardation. Physician’s knowledge of the patient’s history also provided 
an earlier diagnosis for this rare disease. Rogers et al. speculate that early therapeutic 
management is important for future cases as uridine administration may have a role in reducing 
the abnormal effects that can occur in patients. They hypothesize that such effects as mental 
retardation and physical growth disturbances can be reversed with early treatment. The patient 
clearly exemplifies the benefit of early therapy because by the age of 2.5, the patient had 
achieved all developmental milestones for her age. Other cases do not always generate these 
results, even with oral uridine treatment.  
 
CASE REPORT II2 
 
Overview 
 
Imaeda et al. was the first to identify a case of hereditary orotic aciduria in Japan. Though 
previous patients heterozygous for the condition were phenotypically “normal” except for orotic 
aciduria, the case report for the patient (introduced below) exhibited severe symptoms. 
Pyrimidines can be found in mother’s milk and are crucial in the neonatal period and in the 
duration of breast-feeding. For normal patients, de novo pyrimidine synthesis will provide 
sufficient nucleotides important in cellular function and development. However, in a 
homozygote for hereditary orotic aciduria, pyrimidine therapy must be administered. This patient 
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remained deficient in pyrimidines from breast milk and by de novo synthesis for over a week. 
After nine days, administration of dietary pyrimidine was added to the milk of the patient. 
 
 
History, Initial Symptoms, and Laboratory Examination 
The family history of the patient in this case includes members heterozygous for 
hereditary orotic aciduria (type not specified). The patient’s father demonstrated normal enzyme 
activity and was not found to be a carrier for a mutation in UMPS. However, though the patient’s 
mother was phenotypically normal, she was found to be a heterozygote carrier. The patient was 
also found to be a heterozygote carrier. The patient is a three-year old male born to 
nonconsanguineous parents. Born prematurely, the patient was admitted into the NICU (newborn 
intensive care unit). Asphyxia and low blood sugar were determined after Apgar test score 
results and laboratory examination, respectively. The newborn had low birth weight and was 
difficult to feed. Initial computed tomography of the cranium did not signify any abnormal 
mental developments.  
 
Symptoms 
 
The patient’s symptoms included orotic aciduria, neurological defects, and 
developmental delays. In some cases of orotic aciduria, megaloblastic anemia is affiliated with 
orotic aciduria. In the case of this patient, megaloblastic anemia was not identified. By eight 
months old, the patient began to experience developmental abnormalities and impaired motor 
milestones. At thirteen months, the patient was diagnosed with cerebral palsy (spastic 
quadriplegia). In addition, mental retardation progressed in this time frame, becoming most 
apparent at age 3. Imaeda et al proposes that insufficient pyrimidine nucleosides in the neonatal 
period may have led to severe neurological symptoms in this patient. 
 
Diagnostics 
 
Upon urinary analysis, high levels of orotic acid and orotidine were discovered. 
Creatinine excretion is based on 20 mg per kg of body weight. Control patients have orotic acid 
levels of 1.1-1.9 μmol per mmol of creatinine, but the patient had levels of 10.5 μmol.  
Compared to control values of 0.3 to 1.5 for orotidine, the patient had a value of 2.6 μmol. Both 
OPRT and OMPDC activity was very low with a value of 8.3%. Though the father had higher 
levels of activity for both enzymes (94.3% and 88.6% respectively), the heterozygous mother 
had very low activity. Her activity was documented as 4.4% for OPRT and 7.9% for OMPDC. 
 
Therapy/Management 
 
Since the newborn had difficult feeding and low birth weight, therapy included 
intravenous infusion of glucose and minerals. Imaeda et al proposes that for future treatment of 
similar cases, oral uridine therapy must be introduced as soon as possible. If possible, treatment 
should begin from birth and leading up to the month after birth for the ability to mitigate the 
effects of insufficient pyrimidine levels in the cell. 
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INTRODUCTION 
 
The organic acid 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid is most 
commonly known as Orotic acid or “Vitamin B13”. The body can obtain orotic acid exogenously 
from dairy products and root vegetables (i.e. carrots, beets) or synthesize orotic acid 
endogenously through the pyrimidine synthetic pathway commonly found in hepatocytes, 
erythrocytes, and the kidney (See Figure 1).3-6 The mitochondrial enzyme dihydroorotate 
dehydrogenase (DHODH) converts dihydroorotate into orotic acid so that uridine 
monophosphate synthase (UMPS) can catalyze the conversion of orotic acid to uridine 
monophosphate (UMP).6 Orotic acid is mainly found within the cytoplasm of cells. 
As an intermediate in pyrimidine synthesis, orotic acid is important for deoxyribonucleic 
acid (DNA) and ribonucleic acid (RNA) production, diphosphosugar formation within basement 
membranes, and the formation of uridine nucleotides. Though the body can attain pyrimidines 
from the diet, a sufficient amount of pyrimidines to regulate the above cellular processes is 
required. Moreover, it is the endogenous production of pyrimidines that generates the quantity of 
pyrimidines needed to meet the cellular requirement. Thus, when orotic acid is present but not 
able to continue on in the pathway for the synthesis of pyrimidines, DNA/RNA production, 
basement membrane stability, and uridine nucleotide formation is compromised.  
Orotic acid plays a role in the stability of tissues because it is a precursor for uridine 
diphosphate formation. The link between orotic acid and uridine diphosphate is due to the role 
that diphosphosugars have in the abundant connective tissue, collagen. Collagen, which is an 
important protein for strength within connective tissues, requires glycosylation of uridine 
diphosphate to form UDP sugar moieties. Thus, uridine diphosphosugars, which are important 
components of collagen, require sufficient pyrimidine synthesis to provide normal structural 
stability for tissues in the body.  Additionally, membranes within the kidney depend on orotic 
acid for a similar reason. Both the glomerular and tubular basement membrane depend on the 
formation of uridine nucleotides for the formation of thicker membranes. If orotic acid (the 
precursor to uridine nucleotides), is not able to enter the pyrimidine pathway, then the strength of 
these membranes is reduced. Furthermore, orotic acid is also involved in other key metabolic 
pathways, some of which are implicated in certain disease states. Orotic acid is a compound 
found to be associated with the pathways linked to β-Ureidopropionase deficiency, 
Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) and dihydropyrimidinase 
deficiency.3 Orotic acid may also connected with the following diseases: Canavan disease, 
colorectal cancer, Crohn’s disease, and ulcerative colitis.3   
Though normal amounts of orotic acid are essential for pyrimidine synthesis and other 
crucial biochemical processes, excessive amounts of orotic acid can lead to metabolic acidosis 
and have toxic effects on tissues. Excess orotic acid causes harm to tissues because of the role 
that orotic acid plays as an acidogen and a metabotoxin.3 An acidogen is a compound that 
increases acid concentration, which in large quantities can lead to metabolic acidosis.3 An 
increase in hydrogen ion concentration correlates with a decrease in blood pH. If pH levels 
decrease, then the range necessary for normal enzyme function is altered. Thus, acidosis will 
lead to a compromise of enzyme function and also an impairment of cellular function. Based on 
the composition of cells, tissues, organs, and organ systems, when function is impaired at the 
enzymatic level, it will also affect the body’s ability to maintain homeostasis and thus normal 
function. Acidosis is dangerous because it will change the environment for optimal function of 
enzymes within many bodily systems, particularly the cardiovascular and the nervous system. As 
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a metabolite, an accumulation of orotic acid suggests the role that it can play as a metabotoxin. A 
metabotoxin is a compound that releases metabolites that could be damaging or toxic to the cell.3 
When orotic acid donates a proton to a conjugate base, it can form a salt and water in this 
neutralization reaction. Nonetheless, as an acid, the release of protons will contribute to the 
decrease of pH and the increase of toxicity within the plasma.  
 
OROTIC ACID TRANSPORTERS 
 
The solute carrier gene 22 family codes for a subfamily of at least ten transmembrane 
organic anion transporters (OATs), organic cation transporters(OCTs), and organic carnitine 
transporters(OCTNs).7 The structural components of this subfamily of transporters includes 
twelve transmembrane domains, and approximately 540-560 amino acids (See Figure 2).7OATs 
are transport proteins responsible for influx of anions between epithelial barriers and fluids 
throughout the body. Previously, orotic acid transport in the liver and kidney was unknown. 
Evidence that the transporters OAT1, OAT2, OAT4, and hURAT1 play a role in orotic acid 
transport has been discovered.7-9  
OAT1 is found primarily on the basolateral surface of the proximal tubule of the kidney 
as well as in the choroid plexus. Substrates of OAT1 include numerous small xenobiotics, 
polycyclic aromatic hydrocarbon (PAH), cyclic nucleotides, α-ketoglutarate, folate, diuretics, 
nonsteroidal anti-inflammatory drugs (NSAIDs), indoxyl sulfate, prostaglandin E2, toxins, and 
mercurials.7 The mechanism of transport for OAT1 appears to function mainly as an efflux 
transporter in drug removal from the plasma. Metabolomic analysis of wild-type OAT and 
knock-out OAT mice were extracted and further investigated by reverse-phase liquid 
chromatography and mass spectrophotometry.7 The purpose of this research was to determine the 
substrates of OAT in vivo. Findings revealed that if OAT1(SLC22A6) is affected, then there is a 
reduction in the urinary excretion or orotic acid and orotate.7 
OAT2 is found in greatest concentration in the liver, however, it is also found in the 
kidney. The substrates for OAT2 includes antivirals, cGMP, acetylsalicylate, prostaglandin E2, 
dicarboxylates, glutamate, PAH, and salicylate.7 Orotic acid has also been identified as a specific 
substrate for OAT2 (SLC22A7).7 Results from Fork et al. suggest that OAT2 has the following 
roles: 1) it is responsible for the efflux of hepatic glutamate from the cytosol 2) it allows the liver 
to maintain homeostasis for plasma concentrations of glutamate, and 3) transports orotic acid by 
influx (See Figure 3).10 Research studies have confirmed that this function of glutamate efflux 
from cells is conserved across the following organisms: human, rat, pig, and mouse.10 Orotic acid 
may also be effluxed from hepatocytes by OAT2, and this efflux may be accelerated by 
glutamate. If liver failure is occurring, it can impact ureagenesis and the maintenance of 
glutamate concentrations in the plasma. OAT2 may be important to investigate for therapeutic 
intervention in acute glutamate brain toxicity or to increase glutamate efflux by orotic acid 
infusion. 
Two other isoforms are of interest to researchers for their role in orotic acid transport- 
OAT4 and hURAT1.9 OAT4 can be found in the placenta, kidney, and brain and uses estrone 
sulfate, dehydroepiandrosterone sulfate, prostaglandin E2, urate, NSAIDs, antihypertensives, 
uric acid, and ochratoxin A as a substrate.7 However, Anzai et al also discovered that the isoform 
OAT4 (SLC22A11) transports orotic acid into renal proximal tubular cells.7-9 Nigam et al. 
proposes that OAT4 may allow reabsorption of organic acids on the apical membrane of these 
proximal tubular cells.7,8 Regulation of OAT4 transport can be mediated by strong inhibitors 
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such as estrone sulfate, DHEA sulfate, probenecid and benzbromarone.8 Clinically, such 
inhibitors must be further investigated due to the impact that they have on the transport of the 
substrates listed above.  
Lastly, the human urate transporter 1 (hURAT1) can be found in the kidney and utilizes 
urate and orotate as a substrate. The gene SLC22A12 codes for the hURAT1, formerly known as 
renal specific transporter (Rst).7,9 This transporter was first reported to facilitate the transport of 
oratate in renal proximal tubular cells by Miura et al.9 The hURAT1 can be compared to OAT1 
due to functional similarities.7Studies on orotic acid transport are relevant for understanding the 
mechanism for orotic acid excretion. Particularly, since orotic acid crystal formation could lead 
to urinary obstruction, these transporters may be further investigated as possible drug targets in 
cases of orotic aciduria.1 
 
ETIOLOGY OF OROTIC ACIDURIA 
 
The causes of orotic aciduria can be divided into four main categories. First, orotic 
aciduria caused by a defect in pyrimidine synthesis; second, orotic aciduria caused by a defect in 
the urea cycle; third, drug-induced orotic aciduria; and lastly, idiopathic orotic aciduria. The 
primary cause of orotic aciduria is also known as hereditary orotic aciduria. Hereditary orotic 
aciduria, which has three subtypes (type I, II, and III), is due to a genetic defect which 
significantly impairs uridine monophosphate synthetase (UMPS) activity. Reduction in this 
activity impairs the production of pyrimidines, important biological macromolecules that are 
essential for life. Urea cycle defects which cause orotic aciduria are due to enzymes and 
transporters within the urea cycle which are not functioning properly. The urea cycle is the 
process used to remove nitrogenous substances from the body. Since an accumulation of 
nitrogenous substances will impair the brain and other organ systems, the urea cycle is a very 
important process for homeostasis. Drugs such as allopurinol, 5-fluorouracil, and 6-azauridine 
are main inhibitors of the pyrimidine pathway and will also induce orotic aciduria. Idiopathic 
orotic aciduria occurs when other diseases cause an increase in orotic acid excretion in the urine. 
Regardless of the cause generating orotic aciduria, similar symptoms such as motor and mental 
impairment may result. Thus, early diagnosis of the condition and the appropriate therapy can 
reduce the damage which may be caused by sustained orotic aciduria. 
 
OROTIC ACIDURIA DUE TO DEFECTS IN PYRIMIDINE METABOLISM 
 
A pyrimidine is a six-membered heterocyclic ring containing carbon, nitrogen, and 
oxygen. DNA contains pyrimidines such as the nitrogenous bases cytosine (2-hydroxy-4-
aminopyrimidine) and thymine (2, 4-dihydroxy-5-methyl pyrimidine). RNA contains mainly 
cytosine and uracil (2, 4-dihydroxypyrimidine). The combination of the nitrogenous base, a 
deoxyribose sugar, and a phosphate group form the backbone of DNA. Ribonucleic acid is a 
linear structure which contains a nitrogenous base, ribose sugar, and a phosphate group. 
Phosphorylation of these bases will generate a nucleotide. A nucleotide is incorporated into the 
double helical structure within DNA, versus a single, linear strand for RNA.These bases can also 
be mono, di, and triphosphorylated for chemical reactions in the body. Many tissues need to 
synthesize pyrimidines for the regulation of cellular identity and function.  
 
Biochemical Significance of Pyrimidines 
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 The cellular machinery within the body maintains a universal code that is essential for the 
proper development of organ systems, organs, tissues, cells, and the cellular organelles 
governing cell activity. Ultimately, this universal code is affiliated with the macromolecules 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) which are mandatory for life. The 
central dogma of life orchestrates how the instructions for life contained in DNA can be 
converted into a message that the cell uses. First, DNA is important for making more copies of 
the same cell, and DNA to DNA copying occurs through a process called replication. Second, the 
DNA must be converted to RNA through a process known as transcription. Transcription allows 
the genetic information (genes) to be prepared for translation to proteins. The translation of RNA 
to gene products is vital for the regulation of processes involved in metabolism, growth, 
development, aging, disease, etc.   
Pyrimidines are important compounds necessary within the cell cycle for the synthesis of 
genetic information. Genetic information regulates the activity of all cells in the body because it 
contains the manuscript for cellular machinery, is regulated to maintain homeostasis within the 
body, and allows for cellular growth and development. Defects in the synthesis of these 
macromolecules will impact the quantity of bases available for DNA and RNA synthesis. When 
DNA and RNA synthesis is not sufficient, cellular growth and stability is impacted. The 
phosphate groups on these nucleotides may also serve to be used in phosphate transfer reactions. 
The release of phosphate from adenine triphosphate (ATP) and other nucleotides is an important 
source of cellular energy which is required for various biochemical reactions. Biochemical 
reactions including the active transport of substances across the cell membrane, the activation of 
enzymes, the contraction of skeletal muscle, and the inhibition of certain pathways depend on 
phosphate transfer. Specifically, guanine triphosphate (GTP) is a main regulator in protein 
synthesis, uridine triphosphate (UTP) provides energy of activation in the reaction of glucose and 
galactose, and cytidine triphosphate (CTP) plays a role for energy in lipid metabolism. 11,12 
Disruption of the pathway causes problems because the body cannot synthesize these 
compounds, and the normal recycling of these compounds for re-incorporation into DNA or 
RNA (“salvage pathway”) may also be disrupted or insufficient to provide the needs of the cell.    
In addition, β-alanine and β-aminoisobutyrate are formed from the catabolism of 
pyrimidines. Both compounds can be converted into substrates in the energy-producing 
tricarboxylic acid (TCA) cycle.3,11,12 The TCA cycle produces GTP, NADH, and FADH2. The 
TCA cycle is a main producer of 3 molecules of the reducing agents NADH and 2 molecules of 
the compound FADH2 which serve as donors to the electron transport enzymes. For each 
molecule of NADH, the electron transport chain (ETC) can generate 2.5 moles of ATP. For each 
mole of FADH2, about 1.5 moles of ATP. The electron transport enzymes function to generate 
ATP through the electrochemical gradient generated in the mitochondrial matrix. ATP, as 
discussed previously, is the energy investment required for many biochemical processes to 
proceed. 
Pyrimidine synthesis is not only important for DNA and RNA production, but also for 
other biochemical processes. Pyrimidines are used as nucleotide-lipid cofactors to generate stable 
erythrocyte membranes, for cell proliferation, and for the biosynthesis of glycogen and 
phospholipids. The role of pyrimidines can also be identified in cell-mediated immunity.6,13 In 
early development, rapid pyrimidine synthesis is required for neural maturation and 
organogenesis. Thus, mutations with a severe effect on the activity of UMPS can lead to death.14 
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OVERVIEW OF TYPE I, TYPE II, AND TYPE III OROTIC ACIDURIA 
 
A mutation that disrupts the bifunctional activity of uridine 5’- monophosphate synthase 
(UMPS) is the most frequent inborn error of pyrimidine nucleotide synthesis.5 Orotic aciduria 
(type I, II, or III) occurs due to this defect in pyrimidine synthesis. This disease was discovered 
as a rare autosomal recessive disorder in 1959.5,15,16 Hereditary orotic aciduria can be divided 
into three subtypes, two of which are clinically indistinguishable (type I and II) and a third that 
does not present with macrocytic hypochromic megaloblastic anemia (See Table 1).16 In type I, 
both orotate phosphoribosyl pyrophosphate transferase (OPRT) and orotidine monophosphate 
decarboxylase (OMPDC) are defective, whereas in type II, only OMPDC is impacted.16 OPRT 
and OMPDC have been found defective in erythrocytes, leukocytes, fibroblasts, and saliva due to 
a mutation in the individual catalytic sites of UMPS.13 UMPS activity also plays an important 
role in the brain, liver, skeletal muscle, and spleen.14 Defects in pyrimidine synthesis commonly 
lead to mental retardation. 
 
Epidemiology of Disease 
 
Hereditary orotic aciduria is a rare autosomal recessive disorder with a prevalence in 
infants and children of 1:1,000,000.17 There have been only about twenty identified cases 
worldwide.14 Out of these cases, point mutations were discovered in three Japanese families.18 
Further information about this rare disorder is limited. 
 
Biochemical Pathology 
 
There are three subtypes of hereditary orotic aciduria. In the most common type, type I 
orotic aciduria, 90% of patients experience severe loss of both OPRT and OMPDC activities due 
to a deficiency in UMPS.19,20 Studies show that deficient quantities of wild-type UMPS activity 
are responsible for the variation in levels of orotate to orotidine in type I orotic aciduria. 
Erythrocyte activity of OPRT is absent in type I.13 Type II is clinically indistinguishable from 
type I but includes specific inactivation of OMPDC which occurs through an unknown 
mechanism.16,19 Cells will have less than 1% activity of OMPDC and an increase in OPRT 
activity with the type II subtype.20 The orotate levels are comparable to that of type I, but there is 
an increase in the excretion of orotidine. Type III, or hereditary orotic aciduria without 
megaloblastic anemia (OAWA), is correlated with a deficiency in OMPDC. The case where this 
subtype first presented revealed a homozygous missense mutation within a conserved region of 
the OMPDC domain of the UMPS gene (c.928 T4>G; p. Phe310Val).13 In a type III patient, the 
levels of OPRT activity are present but remain low.   
Carbamoyl phosphate is formed intracellularly from glutamine, bicarbonate, and ATP by 
CAD, a cytoplasmic enzyme with active sites for carbamoyl phosphate synthetase II (CPS II), 
aspartate transcarbamoylase, and dihydroorotase (See Figure 5).5 The reaction proceeds with 
CPS II forming carbamoylaspartate, with enzyme-catalyzed cyclization by aspartate 
transcarbamoylase (ATC) to form dihydroorotate, and with dihydroorotate dehydrogenase 
(DHODH) oxidation of dihydroorotate to orotic acid. Orotic acid is converted to uridine 
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monophosphate (UMP) by UMPS.21 The formation of UMP can also occur via a “salvage” 
pathway from uracil phosphoribosyltransferase using uracil and 5-phosphoribosyl-1-
pyrophosphate ([PRPP] See Figure 4).22  
The enzyme uridine monophosphate synthase (UMPS) is essential in this process because 
of its bifunctional regulation of pyrimidine synthesis. This enzyme is involved in the ribosylation 
of orotate to orotidine monophosphate (OMP) via orotate phosphoribosyl pyrophosphate 
transferase (OPRT). UMPS also decarboxylates OMP to uridine monophosphate with OMPDC. 
When the enzyme uridine monophosphate synthase is impaired, there will be a buildup of orotate 
(OA) or orotidine monophosphate (OMP). Though OA is permeable, once it crosses the cell 
membrane it does not undergo any modifications and is excreted. OMP is impermeable and is 
dephosphorylated to form the compound orotidine prior to secretion. Normally, the UMPS 
reaction promotes UMP formation and only generates small amounts of cellular OA and urinary 
OA. In hereditary orotic aciduria, though more cellular orotate and urinary orotate are being 
produced, OA is not able to complete the pathway of pyrimidine synthesis.13  
 
Consecutive phosphorylation of UMP to UDP and UTP occurs by the enzymes uridylate 
kinase and nucleoside diphosphate kinase (NDPK) (See Figure 4). Cytidine triphosphate (CTP) 
and thymidine triphosphate (TTP) can be formed from uridine triphosphate (UTP). Pyrimidine 
synthesis is important for the provision of high energy molecules for biochemical processes and 
for DNA and mRNA synthesis. The regulatory processes that govern pyrimidine synthesis 
include negative feedback by UTP and positive regulation by PRPP upon the CPS II active site 
of CAD (See Figure 4).5,23 Low pyrimidine concentration due to a defect in UMPS will impact 
erythrocyte formation and cause megaloblastic anemia.20 Megaloblastic anemia is usually the 
first manifestation that will occur for this condition because a defect in synthesis of the 
pyrimidine UTP will decrease the synthesis of the other pyrimidines, CTP and TTP as well.18 
This condition results in an inadequate amount of nucleotides for DNA synthesis, causing the 
bone marrow to produce large cells that are unable to undergo cell division. Since cell division is 
impaired, the patient will not be able to develop normal shaped erythrocytes.6,17  
 
Genetic Basis of Disease 
 
Orotic aciduria is a rare, autosomal recessive disorder that can occur due to an inborn 
error in metabolism. Hereditary orotic aciduria occurs with an autosomal recessive mutation of 
3q21.17,24 The UMPS gene is 480 amino acids long with six exons. While the amino acid 
sequence for the UMPS gene has an N-terminal of 214 amino acids and contains OPRT, the C-
terminal of the enzyme is 258 amino acids and contains OMPDC. The underlying genetic defect 
may occur due to biallelic missense mutations which lead to amino acid substitutions.24 These 
mutations decrease the steady-state levels of UMPS, impair UMPS binding ability, and reduce 
UMPS catalytic activity. Variants may include null alleles and missense changes. Upon 
investigation of two type I families, researchers discovered that polymorphisms within exon 
regions may not reduce the function of OPRT or OMPDC, as discovered with G231A and 
440Gpoly.14 
 
Clinical Presentation 
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Patients with hereditary orotic aciduria may present with symptoms primarily before 
twelve months of life.13 Though an alteration in pyrimidine synthesis disrupts many biological 
processes, clinical presentation of UMPS defects mainly includes phenotypic expression of 
mental retardation and neurological dysfunction.13,25 Deficient quantities of pyrimidines will 
impact the stability of erythrocytes, causing macrocytic hypochromic megaloblastic anemia in 
type I and II.19 Neurological deficits occur in type I, II, and III because of a decrease in 
pyrimidine nucleosides which are converted into nucleotides (CTP, UTP, and TTP). Nucleotides 
are important in metabolic reactions and DNA and mRNA synthesis.14 Both type I and II 
hereditary orotic aciduria will present with megaloblastic anemia. Type III does not present with 
megaloblastic anemia, but it is still unclear as to why the bone marrow does not produce 
abnormal erythrocytes in type III patients.22 Heterozygous UMPS-mutations can lead to orotic 
aciduria that appears mild or isolated and does not cause clinical abnormalities.24  
 
Signs/Symptoms 
 
When nucleotide synthesis is impaired, as for patients with UMPS-mutations, then the 
functions of the nervous system, the renal system, the immune system, and the integumentary 
system become compromised. First, insufficient pyrimidines will lead to the manifestation of 
symptoms within the nervous system which include growth retardation, developmental delay, 
intellectual disability, strabismus, motor impairment, and hypotonia.13,24 Symptoms that may 
occur include delayed growth and developmental/psychomotor retardation (type I, II, III), 
congenital malformations (type II), and immune deficiencies (type I,II).20 A patient with type III 
may often suffer from neurological abnormalities, congenital development concerns, and 
developmental delay. However, neurological abnormalities and developmental delays are also 
possible in type I and II. Besides neurological symptoms, the abnormal function of the renal, 
immune, and integumentary system will also generate symptoms within some patients. 
For the renal system, orotic acid crystallizes in the urine because there are large amounts 
of insoluble orotic acid present in the kidneys.2,26,27 Moreover, crystallization can lead to renal 
failure due to the obstruction of the ureters and urethra by crystallized orotic acid. Other signs 
affiliated with this disease include hematuria and splenomegaly.13,27,28 Defects in the immune 
system will occur because nucleotides promote the synthesis of cell types that are necessary in 
cell-mediated immunity and for defense from bacterial and fungal invasion.29 If nucleotide 
synthesis is impaired, then immune function will also become impaired and lead to a reduced 
ability to fight infection. Defective pyrimidine synthesis can vary from normal to low T cell 
number and T-cell mediated cell death, defects in the delayed type hypersensitivity response, and 
reduced T levels of serum IgG and IgA.28 Immunological involvement may also cause 
neutropenia, leukopenia, and lymphopenia (particularly due to infections of candidiasis, fatal 
varicella, and meningitis).13,22,24,30 In regards to the integumentary system, impaired pyrimidine 
synthesis will lead to the generation of scant hair and reduced nail growth. Heterozygous 
individuals exemplify orotic aciduria but are asymptomatic.2 
 
Diagnosis 
 
Most inherited defects of pyrimidine metabolism are difficult to diagnose due to the rarity 
of this condition, heterogeneous presentations which may appear similar to other disorders, and 
their varied phenotypic spectrum which is still under investigation.9 Type I, II, and III orotic 
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aciduria can be differentiated from a urea cycle disorder, as it is not characterized by 
hyperammonemia or an altered amino acid profile. Definitive diagnosis of type I or type II orotic 
aciduria is based on megaloblastic anemia without a deficiency in B12 or folic acid as well as 
abnormal OMPDC/OPRT activity and hyperoroticaciduria.4 Type III diagnosis will be due to 
motor or neurological impairment, as well as to low enzyme activity and hyperoroticaciduria. 
Since pyrimidines will be quickly cleared from blood and CSF by the renal system, the 
best diagnostic marker for pyrimidine deficiencies is through urine analysis.20 Upon urinary 
evaluation, homozygotes may present with more than one millimole(mmol) of orotic acid per 
millimole creatinine, whereas disease free individuals have ∼1 micromole (μmol) orotic acid 
excreted per mmol creatinine.5 Elevated orotic acid levels include concentrations greater than 60 
nanomoles (nmoles) of orotic acid per milligram (mg) of creatine.31 Urinary orotic acid 
concentrations of 500-1000x normal in homozygotes with a UMPS mutation will lead to orotic 
acid crystals, especially during dehydration.2,5,18 Orotate (OA) will be great in concentration 
when the wild-type UMPS is functional. If OMPDC is inhibited, then this factor indicates that 
orotidine monophosphate (OMP) is great in concentration.  Such tests determine the 
concentration of both intracellular amounts of OA and OMP.16An orotate to orotidine ratio above 
10 will occur in type I patients. Type II presents with a orotate to orotidine ratio that is lower 
than type I due to increased orotidine levels. The urinary analyses of patients with type III 
include equimolar orotate to orotidine concentrations, or a ratio of about 1. It is best to diagnose 
this disease within the neonatal or infancy period because if pyrimidine nucleoside supply is 
reduced, it may be the main cause of neurological symptoms.13,28 
 
Prognosis 
 
If hereditary orotic aciduria is detected early, treatment can be administered for the life-
time of the patient. The prognosis for a patient with type I, II, or III orotic aciduria is good if the 
UMPS defect is detected early and if oral uridine treatment is also started early. In addition, due 
to early uridine treatment, then normal psychomotor development may be attainable (See Case 
Study 1).18 Pyrimidine replacement therapy can lead also to remission and reduced urinary orotic 
acid levels.13 Late detection of the disorder may not allow neurological deficits to be reversed. 
Late detection may lead to coma, seizures, or death.  
 
Management 
 
Early diagnosis and a distinction between type I and II orotic aciduria, vitamin B12, and 
folate deficiency must be made for proper treatment. Hereditary orotic aciduria type I and II 
causes hypochromic erythrocytes or megaloblastic bone marrow that are not responsive to 
common hematinic treatments of pyridoxine, iron, folic acid, or vitamin B12.13,22 One of the 
early cases of congenital orotic aciduria was managed with an oral cytidylic-uridylic compound. 
Case Study I discussed earlier also revealed that oral administration of uridine can reduce 
symptoms and restore the patient to normal developmental milestones.1 In 2015, the United 
States Food & Drug Administration approved the drug Uridine triacetate (Xuriden), which was 
developed by Wellstat Therapeutics, Inc. for treatment of hereditary orotic aciduria.32 Xuriden is 
the current drug for lifelong treatment of orotic aciduria type I and II.13,33 Oral uridine is an 
effective therapeutic agent because it can be ingested in granules with milk, formula, applesauce, 
pudding, or yogurt, so it is in a usable form for pyrimidine synthesis.32 The prescription is a 
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single daily dosage of 60 mg/kg, though as long as the dosage is not more than 8g, the patient 
may take up to 120 mg/kg daily.33 Other research discusses the administration of the nucleoside 
uridine in doses of 50–300 mg/kg/ daily as effective therapy. Xuriden provides uridine as the 
substrate for tissue kinase to form UMP. UMP is the precursor for uracil, cytosil, and thymine 
nucleoside synthesis.19 The effectiveness of uridine triacetate to accomplish the completion of the 
de novo pyrimidine synthesis pathway is due to its ability to be transported across the blood-
brain-barrier and into cells throughout the body. Additionally, pyrimidine replacement reduces 
urinary excretion of orotic acid and generates clinical and hematological remission. Treatment 
has not yet been established for type III. 
 
OROTIC ACIDURIA DUE TO UREA CYCLE DEFECTS  
 
Defects in Urea Cycle Enzymes 
 
Orotic aciduria can occur in urea cycle disorders when there is a defect in an enzyme 
such that carbamoyl phosphate builds up. The most common defect in ureagenesis is an X-linked 
deficiency which correlates with impaired activity of the mitochondrial matrix enzyme ornithine 
transcarbamoylase (OTC). 34,35 The prevalence of OTC deficiency has been reported as 
1:40,000.34 A defect in ornithine transcarbamoylase (OTC) will generate orotic aciduria because 
within the urea cycle, OTC is normally responsible for coupling carbamoyl phosphate with 
ornithine to form citrulline.35 If there is a defect in this enzyme, then the levels of carbamoyl 
phosphate build up and are shuffled to an alternate pathway, the pathway for orotic acid 
synthesis (See Figure 6).23 The more carbamoyl phosphate accumulates, the more carbamoyl 
phosphate is pushed into the pathway for the formation of orotic acid. With a deficiency in OTC, 
upon a liver biopsy there is low enzyme activity of OTC after enzymatic assay, low levels of 
citrulline in serum, and hyperammonemia.35,36 In addition, orotic acid can be found in the urine 
of OTC deficient patients.34 The clinical manifestations of OTC deficiency also include lethargy 
and neurological deficits such as coma.37  
With early diagnosis, particularly if family history is revealed, and treatment of the 
hyperammonemia occurs early, then the life expectancy of the patient may increase. When 
knowledge of the family history reveals affected individuals, patients should be monitored in the 
neonatal period because of an increased risk for coma or death.35 Mental retardation may present 
for boys with OTC deficiency forms milder than others. Girls heterozygous for the mutation may 
present with milder symptoms compared to boys.34,35,37 Hyperammonemia can generate coma, 
ataxia, seizures, and cerebral edema in more serious cases.37 Since hyperglutaminemia may also 
accompany the hyperammonemia, it may also be used as a diagnostic tool.35,37 In the case of a 2-
day-old infant whose mother was heterozygous for OTC deficiency, death of the child occurred 
due to the impacts of hyperammonemia.34 Symptoms that can confirm OTC deficiency after 
birth include lethargy, difficulty feeding, respiratory alkalosis, and encephalopathy.34 Treatment 
for this disorder includes the intravenous administration of sodium benzoate, sodium 
phenylacetate, or arginine hydrochloride.37 
There is a slight elevation in urinary orotic acid levels when the urea cycle enzymes 
argininosuccinate lyase (AL), arginase, argininosuccinic synthetase (AS), and arginase are 
defective. (See Figure 6).23 The OTC gene is found on chromosome Xp21.1, primarily in the 
liver. The AS gene is found on chromosome 9q34 and is expressed in the liver and the skin. AL 
can be found on the AL gene of chromosome 7cen-q11.2. Expression of the AL gene is 
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predominant in the liver, skin, and erythrocytes. The ARG1 gene of chromosome 6q23 codes for 
Arginase.  
 AS is an autosomal recessive deficiency which is characterized by both orotic aciduria and 
citrullinemia. With normal AL activity, AL breaks arginosuccinate to fumarate (for the TCA 
cycle) and arginine. Abnormal activity will also lead to an accumulation of orotic acid, due to an 
accumulation of the precursor products in the pathway (See Figure 6).23 Orotic aciduria also 
occurs with the autosomal recessive defect in arginase. Instead of hydrolyzing arginine to 
ornithine and urea in the completion of the urea cycle, this rare disorder leads to an accumulation 
of ammonia, arginine, and orotic acid.38 Therapy for AS and AL deficiency includes 
supplementation of arginine. Arginine supplementation will promote the removal of amino acids 
and nitrogen waste products because arginine will allow citrulline and arginosuccinate to be 
synthesized.39 
In conclusion, it is important to determine whether orotic aciduria is due to a primary or 
secondary factor. To distinguish the specific cause of orotic aciduria, defects in urea cycle 
enzymes may initially be considered. However, laboratory measurements of orotate and 
orotidine can be used in the diagnosis of type I, II, and III hereditary orotic aciduria. Diagnosis 
of primary orotic aciduria (type I, II, III) can be confirmed when the patient does not have 
hyperammonemia. A lack of hyperammonemia eliminates disorders of urea cycle enzymes such 
as ornithinine transcarbamoylase (OTC), argininosuccinate lyase (AL), argininosuccinic 
synthetase (AS), and arginase as the precipitating cause for excess orotic acid in the urine. 
 
Defects in Urea Cycle Transporters 
 
A functional deficiency in the transporters Citrin (aspartate-glutamate transporter) and 
ORNT-1 (ornithine transporter) will also cause elevated orotic acid levels. There will be normal 
arginosuccinic acid (ASA) levels and increased citrulline and arginine plasma levels if either 
transporter is defective. The aspartate-glutamate transporter is coded by the gene CITRIN, found 
on 7q21.3, and is expressed mainly in the liver. ORNT-1 is coded by the ORNT1 gene which is 
found on chromosome 13q14 and expressed in the liver and skin. A second ORNT transporter, 
the hepatic ORNT-2, may also impact orotic acid excretion if it is also defective. 
  
DRUG-INDUCED OROTIC ACIDURIA 
 
Patients should avoid the following pharmacogenetic drugs which further affect 
pyrimidine metabolism: nifedipine and nimodipine. Nifedipine and nimodipine are calcium 
channel blockers that competitively inhibit uridine kinase and OMPDC (See Figure 4).20 Drugs 
such as allopurinol, 5-fluorouracil, and 6-azauridine will lead to an increase in urinary orotic acid 
content by inhibiting the final steps of the pyrimidine pathway. Allopurinol will compete with 
orotic acid for binding to orotate phosphoribosyltransferase. Uracil and de novo pyrimidine 
levels reduce because orotate phosphoribosyl transferase generates the oxypurinol nucleotide 
from allopurinol, and this nucleotide inhibits orotidylate decarboxylase. The influence of 
allopurinol causes a reduction in pyrimidine levels and simultaneous accumulation of orotic acid 
and orotidine in the cell, thus spilling over in high concentration to the urine. The anticancer drug 
5-fluorouracil will worsen orotic aciduria because it is phosphoribosylated by orotate 
phosphoribosyl transferase.  
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The anticancer drug 6-azauridine (6-AZUR) is converted to 6-azauridylate, and 6-
azauridylate will inhibit orotidylate decarboxylase and promote increased orotic acid and 
orotidine excretion (See Figure 7,8). 19,40-42 ATP and Mg2+ are required for phosphorylation of 6-
AZUR.41 Phosphorylated 6-AZUR is responsible for the competitive inhibition of OMPDC.41 
Fallon et al. performed urine analyses of orotic acid on six leukemia patients receiving 
intravenous 6-AZUR dosages for treatment.42 Their investigation of plasma and urine levels of 
orotic acid suggest that highest orotic acid excretion occurs with high dosage of 6-AZUR. These 
dosages are 120-200 mg per kg.42 A second discovery was that orotic acid excretion reduced 
after three days, whereas orotidine excretion in the urine was still evidenced one to three days 
after orotic acid excretion stopped.42 With administration of 6-AZUR, orotidine levels did not 
decline constantly as the orotic acid levels, but instead continued at the same maximum excretion 
value, even when 6-AZUR was removed.42 Since feedback pathways regulate pyrimidine 
synthesis, if 6-AZUR is administered as an anticancer agent, it blocks pyrimidine synthesis and 
increases orotic acid production (See Figure 7,8).41,42 Excess orotic acid may be converted to 
orotidylic acid. As a result, after conversion to orotidylic acid (orotidine 5’-monophosphate), 
orotidylic acid pyrophosphorylase will generate the product orotidine.  
 
IDIOPATHIC OROTIC ACIDURIA 
 
Mitochondrial disorders, hepatic fibrosis, lysinuric protein intolerance, Reye syndrome, 
malignancies, and trauma can also induce orotic aciduria.21 Reye syndrome correlates with 
damaged mitochondria such that carbamoyl phosphate is channeled into orotic acid synthesis. 
Mother’s milk consists of pyrimidine nucleosides, and if feeding is delayed or if an infant 
formula is given without nucleosides to an infant with hereditary orotic aciduria, this could 
correlate with neurological symptoms (See Case Study II).2 
 
CONCLUSION 
 
Though the first identified cases for this disease were in 1959, laboratory examinations, 
early diagnosis, analysis of family history, and prompt treatment with oral uridine is crucial for 
reducing potential motor and neurological impairment. For case study I and II presented above, 
since both the enzymes OPRT and OMPDC had very low activity compared to controls, this is 
why the physicians could propose an inborn error of metabolism. Reflecting on the patients in 
case I and case II, both newborns had low birth weight, difficulty feeding, and low enzyme 
activity. In case I, the presence of megaloblastic anemia suggests a type I or type II hereditary 
orotic aciduria (See Table I). Interestingly, studies have shown that not all cases will present 
with megaloblastic anemia (type III orotic aciduria). Though not specified, this may have been 
the subtype for the male patient in case II (See Table I). Other considerations may be needed 
when discussing the phenotypic severity of disease. For example, when comparing a female to a 
male patient with this disorder, whether or not lyonization has inactivated an X chromosome for 
the female and thus reduced the phenotypic severity of the disease should also be considered.  
Dangers of excess orotic aciduria include acidosis in three forms: organic acidemia, 
organic aciduria, and metabolic acidosis. Acidosis causes mental and physical impairment, so a 
delay in diagnosis and treatment could lead to abnormalities in key organ systems such as the 
brain or heart, seizures, coma or death.3 Children who are treated and live may have 
developmental and intellectual delays. However, as exhibited in case study I, some patients are 
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able to attain normal developmental milestones, birth weight, and birth height. If therapy with 
oral uridine is not administered after an early diagnosis, then in patients with severe phenotypes, 
coma or death may ensue. Early diagnosis of moderate phenotypes can reduce significant mental 
abnormalities. However, whether early diagnosis can reverse any neurological impairment in 
severe phenotypes may need to be studied further. Though hereditary orotic aciduria is a rare 
disease, the impact on de novo pyrimidine synthesis embodies the reason why early symptoms 
should be investigated, why an early diagnosis and analysis of family history is crucial for proper 
therapy, and how combinations of both may increase the potential of life for the patient.  
Several other inborn errors of metabolism besides hereditary orotic aciduria can also lead 
to excess orotic acid in the urine. These inborn errors include the following: argininemia, 
lysinuric protein intolerance/lysurinic protein intolerance syndrome, hyperornithinemia-
hyperammonemia-homocitrullinuria (HHH), ornithine transcarbamoylase (OTC) deficiency, 
citrullinemia type I, and purine nucleoside phosphorylase deficiency.3 However, hereditary 
orotic aciduria (type I, II, III) is principally investigated because it is the most common of these 
errors. Impacts of anticancer drugs on the pyrimidine synthesis pathway could be studied further, 
since addition of these compounds impairs pyrimidine synthesis. Treatment for type III orotic 
aciduria, which is still unknown, should be investigated. Improved databases for identification of 
genetic mutations and categorization of these mutations based on phenotypic severity are needed 
for earlier detection of future cases. Currently, databases are not up to date with the genomic 
deletions involving UMPS. Different databases record deletion and missense variations but 
provide clinicians with little to no information on which mutation is pathogenic or benign. Future 
research should focus on finding better screening methods and thus improved detection of type I, 
II, and III orotic aciduria. Researchers should explore treatment options for type III orotic 
aciduria and further analyze the biochemistry affiliated with the question “Why does type III not 
cause megoblastic anemia?”. Studies of the role of the OAT transporters may help in designing a 
therapy to remove excess orotic acid and to reduce crystalluria. 
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FIGURES 
 
 
 
Figure 1. Orotic Acid (C5H4N2O4) Structure.3 
 
Orotic acid is a precursor to pyrimidine synthesis. It is a 156.1 g/mol compound that functions as 
an acid and a metabolite. In excess, orotic acid can spill over into the urine and form orotic acid 
crystals.  
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Figure 2. Structural Composition of OAT and proposed transport mechanism from blood 
to urine.7 
 
The above figure is the proposed structure of organic anion transporters (OAT). A total of twelve 
transmembrane loops (two pairs of six domains) are present. Two major loops are formed in the 
transporter- the first loop is located extracellularly while the second loop is located 
intracellularly. The first loop contains sites for glycosylation, whereas the second loop between 
sites 6-7 represents the substrate for protein kinase C (PKC) phosphorylation. The termini of the 
protein include an amino (NH2) and carboxy (COOH) terminus which is located within the cell.  
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Figure 3. Renal Proximal Tubule Transport of Organic Anions.7 
 
The above illustration attempts to explain the mechanism of secondary active transport of 
organic anions from the blood to the urine by renal proximal tubule cells. As organic anions 
enter the basolateral side of the tubule from the plasma, the OAT transport system exports 
dicarboxylates from the intracellular space to the plasma. A second transporter, a 
Na+/dicarboxylate symporter, brings both Na+ and carboxylates in from the plasma to the 
tubule. The concentration of dicarboxylate and Na+ couple to allow OAT transport of organic 
anions, but since dicarboxylates are transported against their concentration gradient, the energy 
for this process is also dependent upon the electrochemical gradient established by Na+-K+-
ATPase. Organic anions can be transported into the urine across the apical membrane.  
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Figure 4. De Novo Pyrimidine Synthesis.43,45-52 
 
The pathway for pyrimidine synthesis is illustrated according to the blue arrows. Important 
enzymes for this pathway include: CAD, DHODH, UMPS, CMPK1, NDPK, CTPS, and RRM1 
and RRM2. CAD is the rate-limiting enzyme for pyrimidine synthesis and generation of 
dihydroorotate.45 Dihydroorotate dehydrogenase (DHODH) converts dihydroorotate to orotate.46 
Uridine Monophosphate synthase (UMPS) forms UMP.47 Cytidine/Uridine Monophosphate 
Kinase 1 (CMPK1) is responsible for phosphoryl transfer from ATP to UMP, to CMP, and to 
dCMP.48 Nucleoside diphosphate kinase (NDPK) phosphorylates targets and transfers the γ- 
phosphate from GTP, UTP, and ATP.49 Cytidine Triphosphate Synthase (CTPS) is responsible 
for the rate-limiting step of cytidine triphosphate (CTP) synthesis from uridine triphosphate.50 
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) and Ribonucleotide Reductase 
Catalytic Subunit M2 (RRM2) convert ribonucleotides into deoxyribonucleotides.51,52 
 
 
 
 
 
 
 
 
 
 
 
19
Fonteh: Orotic Aciduria
Published by Scholars Crossing, 2018
 Figure 5. Pyrimidine Synthesis from Carbamoyl Phosphate 5,20,44 
This figure illustrates that carbamoyl phosphate will be translocated to the cytosol for the 
formation of carbamoylasparate by aspartate transcarbamoylase. The amide group of glutamine 
will be used to donate nitrogen and the cyclization of carbamoylasparate forms dihydroorotate. 
Dihydroorotate dehydrogenase(DHODH) will convert dihydroorotate to orotic acid by oxidation 
with NAD+. 5-phosphoribosyl-1-pyrophosphate (PRPP) will donate a ribose phosphate group to 
orotic acid to form orotidylate by pyrimidine phosphoribosyltransferase. The decarboxylation of 
orotidylate generates uridylate by the activity of orotidylate decarboxylase. Uridine 
monophosphate synthase (UMPS) will convert orotic acid to uridine monophosphate (UMP). Not 
shown is the conversion of UMP to UDP by UMP kinase. Next, UDP is converted to UTP, then 
CTP. The active forms of nucleotides exist as triphosphates, so the activity of a monophosphate 
kinase (uridylate kinase) and nucleoside diphosphate kinase is necessary.22 
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 Figure 6. Urea Cycle23 
This figure illustrates the key enzymes of the urea cycle. A deficiency in N-acetylglutamate 
synthase (NAGS) or carbamoyl phosphate synthetase I (CPSI) will not cause orotic aciduria. 
Only a defect in an enzyme within this pathway that leads to an accumulation of carbamoyl 
phosphate will generate the transport of excess carbamoyl phosphate to the cytoplasm to be 
utilized in the pyrimidine cycle. Within the urea cycle, it is deficiencies in the mitochondrial 
ornithine/citrulline transporter, the cytosolic enzymes arginase, argininosuccinate synthetase, and 
argininosuccinate lyase that can lead to an accumulation of carbamoyl phosphate within the 
hepatic mitochondria.23 Arginase deficiency can also lead to orotic aciduria. 
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Figure 7. Synthesis of Pyrimidines is Inhibited by 6-AZUR.42  
 
The drug 6-azauridine (6-AZUR) is able to competitively inhibit enzyme activity of orotidylic 
acid decarboxylase (represented by the blue star), thus preventing the decarboxylation of 
orotidylic acid to uridylic acid. Additionally, the completion of the de novo pyrimidine synthetic 
pathway is disturbed. 
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Figure 8. Lineweaver-Burk Plot of Competitive Inhibition of Orotidylic decarboxylase by 
Azauridine 5’ Phosphate. 41 
 
A kinetic study conducted with 0.05 M Tris Buffer at pH 8 and 25° C generated enzyme units for 
the enzyme that was 0.05/mL. Earlier pH studies determined that at pH 8, the enzyme activity 
was interrupted most significantly by 6-AZUR. The active form of 6-AZUR occurs when the 
compound is in a solution at a pH above 7, and ionized at the carboxylic position.  
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Table 1. Distinguishing features between Type II and Type III Hereditary Orotic 
Aciduria13,16 
 
Distinguishing Features Type I Type II Type III aka Orotic 
Aciduria Without 
Anemia (OAWA) 
Enzyme Impacted 
 
loss of UMPS 
activity- both OPRT 
and OMPDC are 
defective 
specific inactivation of 
OMPDC, mechanism 
is unknown.  
 
an increase in OPRT 
activity 
deficiency in OMPDC 
that can lead to a 
qualitative change in 
UMPS 
 
OPRT activity is 
present but low 
 
Type of mutation autosomal recessive 
mutation 
autosomal recessive 
mutation  
the case where this 
subtype first presented 
revealed a 
homozygous missense 
mutation within a 
conserved region of the 
ODC domain of the 
UMPS gene(c.928 
T4>G; p.Phe310Val) 
Megaloblastic anemia macrocytic 
hypochromic 
megaloblastic anemia 
occurs 
 
macrocytic 
hypochromic 
megaloblastic anemia 
occurs 
 
does not present with 
macrocytic 
hypochromic 
megaloblastic anemia  
 
 
Urinary levels of 
orotate, orotidine 
orotate to orotidine 
ratio above 10  
orotate levels similar to 
type I, but there is an 
increase in orotidine 
levels so the ratio is 
lower 
equimolar orotate to 
orotidine 
concentrations, or a 
ratio of about 1 
Clinical 
distinguishability 
(compared to Type I) 
N/A clinically 
indistinguishable from 
type I 
able to be 
distinguished from 
type I 
Signs/Symptoms Delayed 
growth/development 
Psychomotor 
retardation 
Congenital 
malformations 
Immune deficiencies 
 
Delayed 
growth/development 
Psychomotor 
retardation 
Congenital 
malformations 
Immune deficiencies 
 
delayed 
growth/development 
Psychomotor 
retardation 
neurological 
abnormalities 
Therapy/Effectiveness Therapy includes the 
administration of 
Xuriden 
Therapy includes the 
administration of 
Xuriden 
• Treatment is not yet 
established for type III 
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